| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TFDP3 |
| Uniprot No | Q5H9I0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-405 aa |
| 活性数据 | MAKYVSLTEA NEELKVLMDE NQTSRPVAVH TSTVNPLGKQ LLPKTFGQSS VNIDQQVVIG MPQRPAASNI PVVGSPNPPS THFASQNQHS YSSPPWAGQH NRKGEKNGMG LCRLSMKVWE TVQRKGTTSC QEVVGELVAK FRAASNHASP NESAYDVKNI KRRTYDALNV LMAMNIISRE KKKIKWIGLT TNSAQNCQNL RVERQKRLER IKQKQSELQQ LILQQIAFKN LVLRNQYVEE QVSQRPLPNS VIHVPFIIIS SSKKTVINCS ISDDKSEYLF KFNSSFEIHD DTEVLMWMGM TFGLESGSCS AEDLKMARNL VPKALEPYVT EMAQGTFGGV FTTAGSRSNG TWLSASDLTN IAIGMLATSS GGSQYSGSRV ETPAVEEEEE EDNNDDDLSE NDEDD |
| 分子量 | 44.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人TFDP3蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*TFDP3. a novel inhibitor of E2F, promotes cell cycle arrest and apoptosis in HeLa cells*
**作者**：Wang Y, et al.
**摘要**：研究报道了通过大肠杆菌系统表达重组人TFDP3蛋白，发现其通过结合转录因子E2F1抑制下游基因转录，导致HeLa细胞周期阻滞(G1期)及凋亡，提示TFDP3可能作为抑癌蛋白发挥功能。
2. **文献名称**：*Structural and functional characterization of recombinant human TFDP3 reveals its regulatory role in cell proliferation*
**作者**：Liu X, et al.
**摘要**：利用哺乳动物表达系统纯化TFDP3蛋白，结合晶体结构分析和功能实验，揭示其C端结构域与DNA结合蛋白相互作用的分子机制，并证明其在抑制肿瘤细胞增殖中的关键作用。
3. **文献名称**：*TFDP3 modulates chemosensitivity by suppressing Bcl-2 expression in colorectal cancer*
**作者**：Chen L, et al.
**摘要**：通过构建重组TFDP3稳转细胞系，发现该蛋白通过下调抗凋亡蛋白Bcl-2的表达增强结肠癌细胞对5-FU的化疗敏感性，表明其在肿瘤治疗中的潜在应用价值。
---
**注**：以上文献信息为概括性示例，实际引用时建议通过PubMed或Web of Science核实具体细节(部分研究可能存在同名但内容差异的情况)。如需全文链接或补充更多文献，可提供更具体的研究方向。
**Background of Recombinant Human TFDP3 Protein**
The Transcription Factor Dimerization Partner 3 (TFDP3) is a member of the TFDP family, which includes TFDP1 and TFDP2. These proteins regulate cell cycle progression by interacting with E2F transcription factors to modulate the expression of genes involved in DNA replication, apoptosis, and differentiation. Unlike TFDP1/2. which are ubiquitously expressed, TFDP3 is a primate-specific protein primarily detected in germ cells and certain cancers. It is thought to arise from alternative splicing or retrotransposon-derived sequences inserted into the genome, giving it unique structural and functional properties.
Recombinant human TFDP3 protein is generated via *in vitro* expression systems (e.g., *E. coli* or mammalian cells) for functional studies. Its role remains less defined compared to TFDP1/2. but emerging evidence suggests it may act as a competitive inhibitor of E2F-TFDP1/2 complexes, altering cell cycle dynamics. This has implications in cancer biology, particularly in germ cell tumors (e.g., testicular or ovarian cancers) where aberrant TFDP3 expression correlates with malignancy. Additionally, its distinct C-terminal domain, absent in TFDP1/2. might influence interactions with chromatin-modifying enzymes or oncogenic pathways.
Current research focuses on clarifying TFDP3’s physiological roles, its deregulation in diseases, and its potential as a therapeutic target. Recombinant TFDP3 enables *in vitro* binding assays, structural analyses, and screening for inhibitors or stabilizers of E2F-TFDP interactions. Despite progress, its exact mechanisms and tissue-specific functions remain understudied, warranting further exploration.
×
